nach oben

Cardiovascular Drugs and Therapy

Erschienen in:

01.02.2012

Clinical Trials Update Esc Congress 2011

verfasst von: Robert Rosenson, John Horowitz, Juan-Carlos Kaski, Henry Krum, Willem Remme

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

The role of Vitamin K antagonists such as warfarin as the management of choice for patients with non-valvular atrial fibrillation (AF) at high risk for thrombo-embolism has been central to therapeutics for many years. However, the use of warfarin is associated with the problem of the need for individual effect monitoring, difficulties in achieving good control in some patients, and substantial risk of bleeding and other complications. …

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.PubMedCrossRef

Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–83.PubMedCrossRef

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRef

Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.PubMedCrossRef

Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.PubMedCrossRef

Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–94.PubMedCrossRef

Cohen M. Oral antiplatelet therapy for acute and chronic management of NSTE ACS: Residual ischemic risk and opportunities for improvement. Cardiovasc Drugs Ther. 2009;23:489–99.PubMedCrossRef

Hanna EB, Glancy DL, Saucedo JF. Antiplatelet and anticoagulant therapies in acute coronary syndromes. Cardiovasc Drugs Ther. 2010;24:61–70.PubMedCrossRef

Oldgren J, Budaj A, Granger CB, For the RE-DEEM investigators, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781–9.PubMedCrossRef

10.

Alexander JH, Becker RC, Bhatt DL, et al. on behalf of the APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877/85

11.

Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind phase II trial. Lancet. 2009;374:29–38.PubMedCrossRef

12.

Heeringa M, Groenendaal D, Strabach G, et al. Co-administration of darexaban (YM150), an oral direct factor Xa inhibitor, with acetylsalicylic acid, clopidogrel and naproxen: no evidence of clinically relevant interactions. J Thromb Hemost. 2007;9:360.

13.

Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32:2541–54.PubMedCrossRef

14.

Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre, randomized controlled trial. Lancet. 2003;361:1149–58.PubMedCrossRef

15.

Sever PS, Chang CL, Gupta A, Whitehouse A, Poulter NR, On the behalf of ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 2011;32:2525–32.PubMedCrossRef

16.

Davidson M, Rosenson RS. HDL therapy: The next frontier. Am J Cardiol. 2009;104(10 Suppl):52E–7.PubMedCrossRef

17.

Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators, et al. Effects of torcetrapib in partients at high risk for coronary heart disease. N Engl J Med. 2007;357:2109–22.PubMedCrossRef

18.

Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51:2739–52.PubMedCrossRef

19.

Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443–54.PubMedCrossRef

20.

Fayad ZA, Mani V, Woodward M, For the dal-PLAQUE Investigators, et al. Lancet 2011; Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial. Lancet. 2011;378:1547–59.PubMedCrossRef

21.

Rosenson RS. Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovas Drugs Ther. 2010;24:71–5.CrossRef

22.

Zannad F, McMurray JJV, Krum H, For the EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.PubMedCrossRef

23.

Pitt B, Zannad F, Remme WJ, For the Randomized Aldactone Evaluation Study (RALES) investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.PubMedCrossRef

24.

Pitt B, Remme WJ, Zannad F, For the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef

25.

Mulder P, Barbier S, Chagraoul A, et al. Log-term heart rate reduction induced by the selective I(f) inhibitor ivabradine improves left ventricular function and intrinsic myocardal structure in congestive heart failure. Circulation. 2004;109:1674–9.PubMedCrossRef

26.

Swedberg K, Komjda M, Ohm M, For the SHIFT investigators, et al. Ivabradine and outcomes in chronic heart failure (SHIFT); A randomised, placebo-controlled trial. Lancet. 2010;376:875–85.PubMedCrossRef

27.

Tardiff JC, O’Meara E, Komajda M, On behalf of the SHIFT Investigators, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507–15.CrossRef

28.

Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study. Eur Heart J. 2011;32:2395–404.PubMedCrossRef

29.

Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25:531–7.PubMedCrossRef

Titel: Clinical Trials Update Esc Congress 2011
verfasst von: Robert Rosenson
John Horowitz
Juan-Carlos Kaski
Henry Krum
Willem Remme
Publikationsdatum: 01.02.2012
Verlag: Springer US
Erschienen in: Cardiovascular Drugs and Therapy / Ausgabe 1/2012
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-012-6371-7

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

24.04.2024 ACC 2024 Nachrichten

Eine FFR-gesteuerte komplette Revaskularisation war in einer Studie bei Patienten mit akutem Myokardinfarkt und koronarer Mehrgefäßerkrankung klinisch nicht wirksamer als eine alleinige Revaskularisation der Infarktarterie.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Simvastatin Ameliorates Angiotensin II-Induced Endothelial Dysfunction Through Restoration of Rho-BH4-eNOS-NO Pathway

Stem Cell Therapy for Arterial Restenosis: Potential Parameters Contributing to the Success of Bone Marrow-Derived Mesenchymal Stromal Cells

Cardiovascular Pharmacotherapy can Reduce Mortality

Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial

The Chemical Compound PTC124 Does Not Affect Cellular Electrophysiology of Cardiac Ventricular Myocytes